Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 2
2013 13
2014 7
2015 1
2017 2
2018 2
2020 3
2021 5
2022 3
2023 2
2024 4
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, Kuroda H, Ostoros G, Tran TV, You J, Lee KY, Antonuzzo L, Papai-Szekely Z, Akamatsu H, Biswas B, Spira A, Crawford J, Le HT, Aperghis M, Doherty GJ, Mann H, Fouad TM, Reck M; AEGEAN Investigators. Heymach JV, et al. N Engl J Med. 2023 Nov 2;389(18):1672-1684. doi: 10.1056/NEJMoa2304875. Epub 2023 Oct 23. N Engl J Med. 2023. PMID: 37870974 Clinical Trial.
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.
He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, Lee SY, Lee KY, Nhung NV, Saeteng S, Liu L, Xing L, Gia NH, Murakami S, Han Y, Saavedra MP, Yoon SH, Teixeira CHA, Escriu C, Martinez-Marti A, Blakely CM, Yatabe Y, Dacic S, Rukazenkov Y, Huang X, Dayal A, Chaft JE; NeoADAURA Investigators. He J, et al. J Clin Oncol. 2025 Sep 10;43(26):2875-2887. doi: 10.1200/JCO-25-00883. Epub 2025 Jun 2. J Clin Oncol. 2025. PMID: 40454705 Clinical Trial.
ASCO update: lung cancer.
Absenger G, Terzic J, Bezan A. Absenger G, et al. Memo. 2017;10(4):224-227. doi: 10.1007/s12254-017-0373-x. Epub 2017 Dec 1. Memo. 2017. PMID: 29250201 Free PMC article. Review.
Immune Aging and Immunotherapy in Cancer.
Kaiser M, Semeraro MD, Herrmann M, Absenger G, Gerger A, Renner W. Kaiser M, et al. Among authors: absenger g. Int J Mol Sci. 2021 Jun 29;22(13):7016. doi: 10.3390/ijms22137016. Int J Mol Sci. 2021. PMID: 34209842 Free PMC article. Review.
TERT Expression and Clinical Outcome in Pulmonary Carcinoids.
Werr L, Bartenhagen C, Rosswog C, Cartolano M, Voegele C, Sexton-Oates A, Di Genova A, Ernst A, Kahlert Y, Hemstedt N, Höppner S, Mansuet Lupo A, Pelosi G, Brcic L, Papotti M, George J, Bosco G, Quaas A, Tang LH, Robzyk K, Kadota K, Roh MS, Fanaroff RE, Falcon CJ, Büttner R, Lantuejoul S, Rekhtman N, Rudin CM, Travis WD, Alcala N, Fernandez-Cuesta L, Foll M, Peifer M, Thomas RK, Fischer M; Lung NEN Network. Werr L, et al. J Clin Oncol. 2025 Jan 10;43(2):214-225. doi: 10.1200/JCO.23.02708. Epub 2024 Sep 30. J Clin Oncol. 2025. PMID: 39348606 Free PMC article.
Longitudinal analysis of PD-L1 expression in patients with relapsed NSCLC.
John N, Schlintl V, Sassmann T, Lindenmann J, Fediuk M, Wurm R, Douschan P, Zacharias M, Kalson L, Posch F, Absenger G, Brcic L, Jost PJ, Terbuch A. John N, et al. Among authors: absenger g. J Immunother Cancer. 2024 Apr 11;12(4):e008592. doi: 10.1136/jitc-2023-008592. J Immunother Cancer. 2024. PMID: 38604811 Free PMC article.
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Barth DA, Stanzer S, Spiegelberg JA, Bauernhofer T, Absenger G, Szkandera J, Gerger A, Smolle MA, Hutterer GC, Ahyai SA, Madl T, Posch F, Riedl JM, Klec C, Jost PJ, Kargl J, Stradner MH, Pichler M. Barth DA, et al. Among authors: absenger g. Front Immunol. 2022 Apr 1;13:840207. doi: 10.3389/fimmu.2022.840207. eCollection 2022. Front Immunol. 2022. PMID: 35432362 Free PMC article.
Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Barth DA, Stanzer S, Spiegelberg J, Bauernhofer T, Absenger G, Posch F, Lipp R, Halm M, Szkandera J, Balic M, Gerger A, Smolle MA, Hutterer GC, Klec C, Jost PJ, Kargl J, Stradner M, Pichler M. Barth DA, et al. Among authors: absenger g. Cancer Med. 2022 Aug;11(16):3074-3083. doi: 10.1002/cam4.4675. Epub 2022 Mar 16. Cancer Med. 2022. PMID: 35297215 Free PMC article.
45 results